Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

Relapsing-Remitting Multiple Sclerosis Pipeline Appears Robust With 28+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Published

on

<!– Name:DistributionId Value:8740511 –> <!– Name:EnableQuoteCarouselOnPnr Value:False –> <!– Name:IcbCode Value: –> <!– Name:CustomerId Value:1204938 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:9aeab6e8-3252-4415-8292-416d46cfd6ad –>

New York, USA, Feb. 01, 2023 (GLOBE NEWSWIRE) — Relapsing-Remitting Multiple Sclerosis Pipeline Appears Robust With 28+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

RRMS is the most common subtype (approximately 87%), which is characterized by unpredictable acute attacks followed by periods of remission. The growing number of patients would raise the market and demand for treatments that may cure the sickness, motivating various firms to spend on studies, research, and development in order to give better treatment alternatives.Significant innovations in the treatment of patients with multiple sclerosis (MS) have primarily addressed the frequency of flare-ups in relapsing-remitting MS (RRMS). With the evolution of technology, there has been good success in MS research, particularly in the creation of novel and diverse treatments and therapies in the clinical trial phases, and some of them are in the final trial phases and might be market-ready. 

DelveInsight’s Relapsing-Remitting Multiple Sclerosis Pipeline Insight – 2023 report provides comprehensive global coverage of available, marketed, and pipeline relapsing-remitting multiple sclerosis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the relapsing-remitting multiple sclerosis pipeline domain.

Key Takeaways from the Relapsing-Remitting Multiple Sclerosis Pipeline Report

  • DelveInsight’s relapsing-remitting multiple sclerosis pipeline report depicts a robust space with 28+ active players working to develop 28+ pipeline therapies for Relapsing-Remitting Multiple Sclerosis treatment. 
  • Key relapsing-remitting multiple sclerosis companies such as Novartis, Sanofi, Cinnagen, Polpharma Biologics, Immunic, Mapi Pharma, Biocad, Apimeds, Genentech (Roche), Merck, Immune Response BioPharma, Clene Nanomedicine, InnoCare Pharma, Oryzon Genomics, GeNeuro SA, AbbVie, Emerald Health Pharmaceuticals, GlaxoSmithKline, RedHill Biopharma, and others are evaluating new drugs for relapsing-remitting multiple sclerosis to improve the treatment landscape.
  • Promising relapsing-remitting multiple sclerosis pipeline therapies in various stages of development include Remibrutinib, Tolebrutinib, Pegylated interferon beta-1a, Natalizumab, IMU 838, GA Depot, BCD-132, Apitox, Fenebrutinib, Evobrutinib, NeuroVax, CNM-Au8, Orelabrutinib, Vafidemstat, Temelimab, Elezanumab, EHP-101, Belimumab, RHB-104, and others.
  • In March 2022, Pipeline Therapeutics is set to commence the Phase Ib/IIa clinical trial of its lead programme, PIPE-307, to treat relapsing-remitting multiple sclerosis (RRMS) patients.  The move comes after the company obtained clearance for its investigational new drug application from the US Food and Drug Administration (FDA) to launch the trial. An oral, selective muscarinic M1 receptor antagonist, PIPE-307, is being developed for restoring myelin to treat MS.
  • In July 2021, InnoCare received $125 million upfront in return for sharing rights to orelabrutinib, an orally-active BTK drug that can cross the blood-brain barrier and penetrate the central nervous system. It is currently in a phase 2 trial for relapsing-remitting multiple sclerosis (RRMS). The deal was back-ended with up to $812.5 million in milestone payments if the drug reaches development, regulatory and commercial milestones, and royalties on any future sales.

Request a sample and discover the recent advances in relapsing-remitting multiple sclerosis treatment drugs @ Relapsing-Remitting Multiple Sclerosis Pipeline Report

The relapsing-remitting multiple sclerosis pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage relapsing-remitting multiple sclerosis drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the relapsing-remitting multiple sclerosis clinical trial landscape.

Relapsing-Remitting Multiple Sclerosis Overview

Multiple sclerosis is the most common neurological disorder in young adults, with symptoms typically appearing between the ages of 20 and 40. Multiple sclerosis attacks the central nervous system’s axons, which are protected by myelin, also known as white matter. Relapsing-remitting multiple sclerosis is the most common type, accounting for approximately 85% of all multiple sclerosis patients. It is distinguished by relapses (or exacerbations) of symptoms followed by periods of remission, during which multiple sclerosis symptoms improve or disappear.

There are several unusual and rare types of multiple sclerosis. Some people with relapsing-remitting MS experience various multiple sclerosis symptoms that appear to be linked to specific triggers. Exacerbations (also known as recurrences, relapses, or seizures) are acute flare-ups of multiple sclerosis symptoms or the appearance of new symptoms that last for at least 24 h.

Find out more about relapsing-remitting multiple sclerosis treatment drugs @ Drugs for Relapsing-Remitting Multiple Sclerosis Treatment 

A snapshot of the Relapsing-Remitting Multiple Sclerosis Pipeline Drugs mentioned in the report:

Drugs Company Phase  MoA RoA
IMU-838 Immunic Phase III Dihydroorotate dehydrogenase inhibitors Oral
Fenebrutinib Roche Phase III Agammaglobulinaemia tyrosine kinase inhibitors Oral
Divozilimab Biocad Phase III CD20 antigen inhibitors Intravenous
Vafidemstat Oryzon Genomics Phase II Lysine specific demethylase 1 inhibitors; Monoamine oxidase B inhibitors Oral
Temelimab GeNeuro SA Phase II Toll-like receptor 4 antagonists Intravenous
Elezanumab AbbVie Phase II RGMA protein inhibitors Intravenous

Learn more about the emerging Relapsing-Remitting Multiple Sclerosis pipeline therapies @ Relapsing-Remitting Multiple Sclerosis Clinical Trials

Relapsing-Remitting Multiple Sclerosis Therapeutics Assessment

The relapsing-remitting multiple sclerosis pipeline report proffers an integral view of relapsing-remitting multiple sclerosis emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

Scope of the Relapsing-Remitting Multiple Sclerosis Pipeline Report 

  • Coverage: Global 
  • Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
  • Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Therapeutics Assessment By Route of Administration: Intravenous, Intradermal, Oral, Subcutaneous, Intramuscular
  • Therapeutics Assessment By Molecule Type: Small Molecule, Gene Therapy, Peptide, Immunotherapy, Cell Therapy
  • Therapeutics Assessment By Mechanism of Action: Dihydroorotate dehydrogenase inhibitors, Agammaglobulinaemia tyrosine kinase inhibitors, Lysine specific demethylase 1 inhibitors, Monoamine oxidase B inhibitors, Toll-like receptor 4 antagonists, RGMA protein inhibitors, CD20 antigen inhibitors
  • Key Relapsing-Remitting Multiple Sclerosis Companies: TG Therapeutics, Novartis, Sanofi, Cinnagen, Polpharma Biologics, Immunic, Mapi Pharma, Biocad, Apimeds, Genentech (Roche), Merck, Immune Response BioPharma, Clene Nanomedicine, InnoCare Pharma, Oryzon Genomics, GeNeuro SA, AbbVie, Emerald Health Pharmaceuticals, GlaxoSmithKline, RedHill Biopharma, and others
  • Key Relapsing-Remitting Multiple Sclerosis Pipeline Therapies: Remibrutinib, Tolebrutinib, Pegylated interferon beta-1a, Natalizumab, IMU 838, GA Depot, BCD-132, Apitox, Fenebrutinib, Evobrutinib, NeuroVax, CNM-Au8, Orelabrutinib, Vafidemstat, Temelimab, Elezanumab, EHP-101, Belimumab, RHB-104, and others.

Dive deep into rich insights for new drugs for relapsing-remitting multiple sclerosis treatment; visit @ Relapsing-Remitting Multiple Sclerosis Medications

Table of Contents

1. Relapsing-Remitting Multiple Sclerosis Pipeline Report Introduction
2. Relapsing-Remitting Multiple Sclerosis Pipeline Report Executive Summary
3. Relapsing-Remitting Multiple Sclerosis Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Relapsing-Remitting Multiple Sclerosis Clinical Trial Therapeutics
6. Relapsing-Remitting Multiple Sclerosis Pipeline: Late Stage Products (Pre-registration)
7. Relapsing-Remitting Multiple Sclerosis Pipeline: Late Stage Products (Phase III)
8. Relapsing-Remitting Multiple Sclerosis Pipeline: Mid Stage Products (Phase II)
9. Relapsing-Remitting Multiple Sclerosis Pipeline: Early Stage Products (Phase I)
10. Relapsing-Remitting Multiple Sclerosis Pipeline Therapeutics Assessment
11. Inactive Products in the Relapsing-Remitting Multiple Sclerosis Pipeline
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products in the Relapsing-Remitting Multiple Sclerosis Pipeline
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

For further information on the relapsing-remitting multiple sclerosis pipeline therapeutics, reach out @ Relapsing-Remitting Multiple Sclerosis Treatment Drugs

Related Reports

Multiple Sclerosis Market

Multiple Sclerosis Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key multiple sclerosis companies, including TG Therapeutics, Immunic, Atara Biotherapeutics, ANOKION, ImStem Biotechnology, among others.

Multiple Sclerosis Epidemiology Forecast

Multiple Sclerosis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted multiple sclerosis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Multiple Sclerosis Pipeline

Multiple Sclerosis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key multiple sclerosis companies, including TG Therapeutics, Immunic, Atara Biotherapeutics, ANOKION, ImStem Biotechnology, among others.

Relapsing Multiple Sclerosis Pipeline

Relapsing Multiple Sclerosis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key relapsing multiple sclerosis companies, including ASLAN Pharmaceuticals, GlaxoSmithKline, Lucid Psycheceuticals, Voronoi, Hanmi Pharmaceutical, among others.

Chronic Progressive Multiple Sclerosis Pipeline

Chronic Progressive Multiple Sclerosis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key chronic progressive multiple sclerosis companies, including Sarepta Therapeutics, BrainStorm Cell Limited, CytoDyn, Pear Therapeutics, ABION, among others.

Primary Progressive Multiple Sclerosis Pipeline

Primary Progressive Multiple Sclerosis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key primary progressive multiple sclerosis companies, including Atara Biotherapeutics, AB Science, Sanofi, MediciNova, among others.

Other Trending Reports

Treatment Resistant Depression Market | Advanced Renal Cell Carcinoma Market | Brain Cancer Market | Centronuclear Myopathy Market | Head And Neck Squamous Cell Carcinoma Market | Acquired Immunodeficiency Syndrome Market | Acute Intermittent Porphyria Market | Neurovascular Devices Market | Defibrillators Market | Ventricular Hypertrophy Market | Urolithiasis Market | Alopecia Areata Market | Autonomic Dysfunction Market | Acute Ischemic Stroke Ais Market | Adenoid Cystic Carcinoma Market | Aspergillosis Market | Biliary Atresia Market | Biliary Tumor Market | Chronic Inducible Urticaria Market | Chronic Insomnia Market | Critical Limb Ischemia Market | Endometriosis Pain Market | Generalized Anxiety Disorder Gad Market | Hallux Valgus Market | Hemophilia B Market | Immunologic Deficiency Syndrome Market | Neuroblastoma Market | Neuromodulation Devices Market | Neurovascular Thrombectomy Devices Market | Osteosarcoma Market | Pemphigus Vulgaris Market | Progressive Familial Intrahepatic Cholestasis Market | Pruritus Market | Radiation Toxicity Market | Pulmonary Hypertension Associated With Interstitial Lung Disease Market | Cluster Headaches Market | Foot And Ankle Devices Market | Intravenous Immunoglobulin Market | Bile Duct Neoplasm Market | Blood Glucose Monitoring Systems Market | Rett Syndrome Market | Tissue Heart Valves Market | Cardiac Biomarkers Testing Devices Market | Subscription Healthcare | Hepatorenal Syndrome Market | Central Venous Catheters Market | Continuous Renal Replacement Therapy Machines Market | Nonalcoholic Steatohepatitis Market | Necrotizing Enterocolitis Market | Cardiac Amyloidosis Market | Artificial Iris Market | Aortic Aneurysm Stent Grafts Market | Polypoidal Choroidal Vasculopathy Market | Adrenal Crisis Market | Hearing Implants Market | Image Guided Surgery Devices Market | Angioedema Market | Bladder Cancer Market

Related Healthcare Services

Healthcare Business Consulting

Healthcare Competitive Intelligence Services

Healthcare Asset Prioritization Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. 

Connect with us at LinkedIn 


GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

Stamus Networks Participates in NATO CCDCOE Locked Shields Exercise

Published

on

stamus-networks-participates-in-nato-ccdcoe-locked-shields-exercise

Leading network-based threat detection and response company part of international contingent lending personnel and technology to support world’s largest live-fire cyber defense exercise
TALLINN, Estonia, April 24, 2024 /PRNewswire/ — Stamus Networks, a global provider of high-performance network-based threat detection and response (NDR) systems, today announced its participation in Exercise Locked Shields, the largest and most complex international live-fire cyber defense exercise in the world. The annual event, which takes place this week, is organized by the NATO Cooperative Cyber Defence Centre of Excellence (CCDCOE) and aims to provide a multinational platform for enhancing partners’ cyber resilience and cooperation capabilities in a high-paced, crisis-like environment.

The exercise pits Red Teams (attackers) against Blue Teams (defenders), utilizing realistic scenarios, cutting-edge technologies, complex networks and diverse attack methods. Teams of civil and military experts must cooperate to defend critical infrastructure systems from cyberattacks.
“This exercise is a demonstration of the power of international cooperation, transcending borders, and uniting a diverse community of experts from the public and private sectors and academia,” said LtC Urmet Tomp, exercise director at NATO CCDCOE. “We are grateful for the dedication and expertise of our allies and all our partners, which are crucial in building a resilient global cyber defense.”
Since 2016, the Stamus Networks team has partnered with CCDCOE in exercises, including Locked Shields and Crossed Swords, contributing expert personnel and putting its Stamus Security Platform (SSP), the company’s flagship network-based threat detection and response system, to the test.
“True cyber resilience must be accomplished through collaboration, and there’s no better example of that on the international level than Exercise Locked Shields,” said Stamus Networks’ CEO Ken Gramley. “The lessons learned and key takeaways from the live-fire exercises that we’ve participated in over the years have been instrumental in helping organizations around the world build up defenses against today’s sophisticated cyber threats. We look forward to collaborating with experts again at this year’s exercise, not only to strengthen our own solutions, but to help defenders elevate their status as cyber heroes around the world.”
To learn more about the NATO CCDCOE and Exercise Locked Shields, visit the website: https://ccdcoe.org/exercises/locked-shields/.
About Stamus Networks: Stamus Networks believes in a world where defenders are heroes, and a future where those they protect remain safe. As organizations face threats from well-funded adversaries, we relentlessly pursue solutions that make the defender’s job easier and more impactful. The global leader in Suricata-based network security solutions, Stamus Networks helps enterprise security teams know more, respond sooner and mitigate their risk with insights gathered from cloud and on-premise network activity. Our Stamus Security Platform combines the best of intrusion detection (IDS), network security monitoring (NSM), and network detection and response (NDR) systems into a single solution that exposes serious and imminent threats to critical assets and empowers rapid response. For more information visit: stamus-networks.com.
Logo – https://mma.prnewswire.com/media/1781381/4666296/stamus_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/stamus-networks-participates-in-nato-ccdcoe-locked-shields-exercise-302125761.html

Continue Reading

Artificial Intelligence

Appdome MOBILEBot™ Defense Empowers Mobile Brands to Equalize Web Application Firewall Performance and Stop Bots Attacks Better

Published

on

appdome-mobilebot™-defense-empowers-mobile-brands-to-equalize-web-application-firewall-performance-and-stop-bots-attacks-better

New adaptive defense model allows network security teams to adjust detection and defense rules to get the most out of existing web application firewalls.
REDWOOD CITY, Calif., April 24, 2024 /PRNewswire/ — Appdome, the mobile app economy’s one-stop shop for mobile app defense, today announced three new enhancements to its MOBILEBot™ Defense solution to empower mobile brands to get more value and control from their existing web application firewall (WAF) infrastructures by adjusting the evaluation, detection, and defense policy to suit each WAF product and installation.

Cybercriminals have shifted their focus to mobile bot attacks, including weaponizing mobile apps, modified mobile apps, malware controlled mobile apps, fake mobile apps, as well as the common bot tactics like bot farms and scripts to perform brute force account takeovers, DDoS attacks and API abuse. WAF vendors have responded by providing customers with anti-bot SDKs. However, anti-bot SDKs impose too much work and too many limits on mobile app developers with too heavy a performance penalty on mobile apps in production. In addition, using these anti-bot SDKs also require costly changes to WAF infrastructures. Appdome MOBILEBot Defense provides the only way to avoid these complex challenges, making it easy for customers to deliver mobile anti-bot defense on top of any installed WAF.
The Appdome MOBILEBot Defense solution is fully portable across all new and old, on-premise and cloud WAFs. The new enhancements to MOBILEBot Defense provide adaptive evaluation, detection and defense rules that can ease and balance the compute burden on existing WAFs and infrastructures, enabling mobile brands to proactively identify and thwart bot attacks, all while reducing the strain on traditional WAFs, including those WAFs reaching their end-of-service horizons. The new Appdome enhancements allow enterprises, network security teams and mobile brands to extend the useful life of WAFs and deliver more ROI from their existing WAF investments.
“Mobile brands need to stop bot attacks, but they also need to get the most out of their WAF infrastructures and avoid costly or unplanned WAF upgrades,” said Tom Tovar, CEO and co-creator of Appdome. “Any mobile brand will likely have multiple WAFs, each with different performance characteristics. Our goal is to allow the brand to tailor the bot defense profile to meet the performance characteristics of each WAF.”
The new innovations in Appdome MOBILEBot Defense include:
Appdome DEVICETrust™: DEVICETrust is an innovative way to set the evaluation mode for connection requests and screen bot traffic and attacks. With it, mobile brands have the power to set the trust level for each threat vector and, depending on the trust setting, determine where, when and how bot detection and defense is performed. This allows for customizable trust models based on the class and type of WAF used in the bot defense infrastructure. With the new trust model mobile brands can select and prioritize the security checks that are most important to their mobile app security project goals with the click of a button.
Three modes of DEVICETrust are available with Appdome MOBILEBot Defense:
Adaptive Trust – uses the Appdome Bot Defense Framework™ intelligence to dynamically adjust the evaluation model based on the responsiveness of each WAF connected to MOBILEBot defense. Runtime-Trust – allows connection requests to proceed while threat assessment and checks are in process.Zero-Trust – holds connection requests until threat assessment and checks are complete.Appdome Bot Source and BotID:  Bot Source and BotID give mobile brands the ability to achieve continuous risk assessments by adding any data, such as business logic, to specific users and sessions in a mobile app, giving the WAF more granular rules and automated enforcement at the point of the attack, including on connection, at login, transaction, password reset, or other key application workflows.
Appdome Client Rate Limiting: Client rate limiting leverages the compute and processing power of the mobile device used in the attack, performing rate-limiting enforcement within the mobile app. Configurable limits on how frequently a user can perform an action, such as attempting to log in, within a defined timeframe. This approach is better than only relying solely on server-side rate limiting which can be susceptible to brute force and DDoS attacks.
“We’re working hard to ensure that our customers get the most out of their WAF infrastructure,” said Chris Roeckl, Appdome chief product officer. “WAFs are high performance, very capable, platforms. The antibot SDKs provided by WAF vendors are not. We’re trying to bridge the gap and give mobile brands something they can use to stop bots quickly, easily and efficiently.” 
About Appdome MOBILEBot Defense Appdome MOBILEBot Defense is the industry’s only comprehensive and fully portable anti-bot defense solution built-from-the-ground-up for mobile apps. It offers mobile brands multi-layered bot detection, intelligence, and defense all in one solution, easily protecting the mobile channel from 300+ attack vectors including fake apps, weaponized apps, malware-controlled apps, bot attacks, credential stuffing, DDoS and account takeovers (ATOs). It requires no SDK, no coding, and no added servers to deploy, and is fully compatible with all coding languages and frameworks used in mobile app development. Appdome MOBILEBot Defense is also the only product to work seamlessly with any WAF used in a mobile brand’s network. With Appdome, mobile brands are more efficiently and effectively protected from bot-driven malicious attacks, fraud, IP theft, performance drains and compliance issues at lower cost and complexity than legacy approaches.  For more information about Appdome MOBILEBot Defense, see our Knowledge Articles at  https://www.appdome.com/how-to/mobile-bot-detection/mobile-bot-defense/mobilebot-detection/.
About Appdome The Appdome mission is to protect every mobile app in the world and the people who use mobile apps in their lives and at work. Appdome provides the mobile industry’s only Unified Mobile App Defense platform, powered by a patented mobile coding engine, Threat-Events™ Threat-Aware UX/UI Control, and ThreatScope™ Mobile XDR. Using Appdome, mobile brands eliminate complexity, ship faster and save money by delivering 300+ Certified Secure™ mobile app security, anti-malware, anti-fraud, mobile anti-bot, anti-cheat, geo compliance, MiTM attack prevention, code obfuscation, social engineering and other protections in Android and iOS apps with ease, inside the mobile DevOps and CI/CD pipeline. Leading financial, healthcare, government and m-commerce brands use Appdome to protect Android and iOS apps, mobile customers and mobile businesses globally. Appdome holds several patents including U.S. Patents 9,934,017 B2, 10,310,870 B2, 10,606,582 B2, 11,243,748 B2 and 11,294,663 B2. Additional patents pending.
Logo – https://mma.prnewswire.com/media/772169/AppDome_Logo_9_27_23.jpg

View original content:https://www.prnewswire.co.uk/news-releases/appdome-mobilebot-defense-empowers-mobile-brands-to-equalize-web-application-firewall-performance-and-stop-bots-attacks-better-302125390.html

Continue Reading

Artificial Intelligence

“Sopra Steria” is positioned as a Leader in the 2024 SPARK MatrixTM for Cloud-Native Application Development Services by Quadrant Knowledge Solutions

Published

on

“sopra-steria”-is-positioned-as-a-leader-in-the-2024-spark-matrixtm-for-cloud-native-application-development-services-by-quadrant-knowledge-solutions

The Quadrant Knowledge Solutions SPARK Matrix™ provides competitive analysis & ranking of the Cloud-Native Application Development Services (CNADS) vendors.  Sopra Steria, with its comprehensive technology for Cloud-Native Application Development Services, has received strong ratings across the parameters of technology excellence and customer impact.PARIS, April 24, 2024 /PRNewswire/ — Sopra Steria and Quadrant Knowledge Solutions announced today that Sopra Steria has been named as a leader in the Q1 2024 SPARK MatrixTM analysis of the global CNADS market.

 
 
The Quadrant Knowledge Solutions’ SPARK Matrix™: Cloud-Native Application Development Services, includes a detailed analysis of global market dynamics, major trends, vendor landscape, and competitive positioning. The study provides competitive analysis and ranking of the leading technology vendors in the form of its SPARK Matrix™. The study offers strategic information for users to evaluate different provider capabilities, competitive differentiation, and market position.
According to Sitaparna Roy, Analyst at Quadrant Knowledge Solutions, “Sopra Steria through its Modern Apps Development Services helps organizations to convert their ideas into Minimum Viable Product (MVP) and monitor all the development stages to production with unparalleled speed, efficiency, and productivity. It facilitates this by offering Enterprise Architect Services, Low- code/ No-code services and Cloud-Native Application development Services in its Modern Apps Development Services portfolio. […] It supports innovation through adoption of the latest technologies and tools for generating new ideas for products, services, and tools. Sopra Steria’s unique ‘BizDevSecOps’ approach for end-to-end digital transformation supports effective communication and collaboration between businesses and team operations throughout the software development life cycle.”
“Sopra Steria is proud to be recognized once again as a leader in Cloud-Native Application Development Services by Quadrant Knowledge Solutions. Our commitment to innovation, customer-centricity, and excellence in service delivery has enabled us to maintain this position for the third consecutive year. We believe that our comprehensive approach to modern application development, supported by our Cloud Center of Excellence and Ingine Platform, empowers organizations to achieve their digital transformation goals efficiently and effectively.”, comments Yann Gloriau, Cloud expert at Sopra Steria.
Click here to know more.
Logo – https://mma.prnewswire.com/media/1861938/4668457/Sopra_Steria_Logo.jpg
CONTACT: Aurélien Flaugnatti, [email protected]
 

View original content:https://www.prnewswire.co.uk/news-releases/sopra-steria-is-positioned-as-a-leader-in-the-2024-spark-matrixtm-for-cloud-native-application-development-services-by-quadrant-knowledge-solutions-302126053.html

Continue Reading
Advertisement
Advertisement

Latest News

Trending